Bixiye
QP83-23 Commercial Pharmacy Benefit Exclusion for Budesonide-Formoterol Aerosol Inhaler and Tiotropium Bromide Inhalation Capsule
Taariikhda uu dhaqangalayo barnaamijka: Okt 11, 2023
Natiijooyinka Raadinta
Soo bandhiga 1231 - 1240 ee natiijooyinka 4296
Bixiye
QP84-23 Commercial Pharmacy Benefit Update: Revised Drug-Related Prior Authorization (PA) Requirement Notification, Effective December 1, 2023
Taariikhda uu dhaqangalayo barnaamijka: Okt 11, 2023
Bixiye
QP85-23 MHCP Pharmacy Benefit Exclusion for Beyfortus™, Daxxify®, Elrexfio™, Izervay™, Talvey™, and Veopoz™
Taariikhda uu dhaqangalayo barnaamijka: Okt 11, 2023
Bixiye
QP86-23 MHCP Pharmacy Benefit Update: New and Revised Drug-Related Prior Authorization (PA) Requirement Notification, Effective November 1, 2023
Taariikhda uu dhaqangalayo barnaamijka: Okt 11, 2023
Bixiye
QP87-23 Availity Essentials Updated Claim Entry Forms
Taariikhda uu dhaqangalayo barnaamijka: Okt 11, 2023
Bixiye
P67-23 Expansion of the Peer Specialist Benefit
Taariikhda uu dhaqangalayo barnaamijka: Okt 02, 2023
Bixiye
P69-23 eviCore Healthcare Specialty Utilization Management (UM) Program: Medical Oncology Drug Prior Authorization Updates
Taariikhda uu dhaqangalayo barnaamijka: Okt 02, 2023
Bixiye
P70-23 New Medical, Medical Drug and Behavioral Health Policy Management Updates: Effective December 4, 2023
Taariikhda uu dhaqangalayo barnaamijka: Okt 02, 2023
Bixiye
P71-23 Medical Policy Updates: Coupe Health and Self-Funded Benefit Plans managed by Blue Cross and Blue Shield of Alabama
Taariikhda uu dhaqangalayo barnaamijka: Okt 02, 2023